{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:18:32Z","timestamp":1778753912598,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,14]]},"DOI":"10.7759\/cureus.108827","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:32:12Z","timestamp":1778751132000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Iatrogenic Tricuspid Regurgitation"],"prefix":"10.7759","author":[{"given":"In\u00eas","family":"Amaral Pinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Rei Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade R","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007, 356:29-38. 10.1056\/NEJMoa062222","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya S","year":"2009","unstructured":"Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet. 2009, 374:577-85. 10.1016\/S0140-6736(09)60252-X","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.181255","article-title":"The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease","volume":"338","author":"Kekewska A","year":"2011","unstructured":"Kekewska A, H\u00fcbner H, Gmeiner P, Pertz HH. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease. J Pharmacol Exp Ther. 2011, 338:381-91. 10.1124\/jpet.111.181255","journal-title":"J Pharmacol Exp Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70225-X","article-title":"A reassessment of risks and benefits of dopamine agonists in Parkinson's disease","volume":"8","author":"Antonini A","year":"2009","unstructured":"Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol. 2009, 8:929-37. 10.1016\/S1474-4422(09)70225-X","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao A","year":"2008","unstructured":"Colao A, Galderisi M, Di Sarno A, et al.. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008, 93:3777-84. 10.1210\/jc.2007-1403","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-0507-8","article-title":"Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study","volume":"20","author":"Budayr A","year":"2020","unstructured":"Budayr A, Tan TC, Lo JC, Zaroff JG, Tabada GH, Yang J, Go AS. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocr Disord. 2020, 20:25. 10.1186\/s12902-020-0507-8","journal-title":"BMC Endocr Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline","author":"Stiles CE","year":"2018","unstructured":"Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline. J Clin Endocrinol Metab. 2018, 10.1210\/jc.2018-01071","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.196010","article-title":"Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma","volume":"21","author":"Khare S","year":"2017","unstructured":"Khare S, Lila AR, Patil R, Phadke M, Kerkar P, Bandgar T, Shah NS. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma. Indian J Endocrinol Metab. 2017, 21:154-9. 10.4103\/2230-8210.196010","journal-title":"Indian J Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.01920.x","article-title":"Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma","volume":"39","author":"Cawood TJ","year":"2009","unstructured":"Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Intern Med J. 2009, 39:266-7. 10.1111\/j.1445-5994.2009.01920.x","journal-title":"Intern Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00139","article-title":"The third case of cabergoline-associated valvulopathy: the value of routine cardiovascular examination for screening","volume":"2","author":"Caputo C","year":"2018","unstructured":"Caputo C, Prior D, Inder WJ. The third case of cabergoline-associated valvulopathy: the value of routine cardiovascular examination for screening. J Endocr Soc. 2018, 2:965-9. 10.1210\/js.2018-00139","journal-title":"J Endocr Soc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EO-22-0086","article-title":"Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma","volume":"3","author":"Hayes AG","year":"2023","unstructured":"Hayes AG, Shirazi MG, Thiyagarajah A, Torpy DJ, De Sousa SM. Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. Endocr Oncol. 2023, 3:e220086. 10.1530\/EO-22-0086","journal-title":"Endocr Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70212-8","article-title":"The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data","volume":"3","author":"Caputo C","year":"2015","unstructured":"Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015, 3:906-13. 10.1016\/S2213-8587(14)70212-8","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476401-severe-iatrogenic-tricuspid-regurgitation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:32:14Z","timestamp":1778751134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476401-severe-iatrogenic-tricuspid-regurgitation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.108827","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}